MiniMed Group, Inc. (MMED) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Multiple concerning factors at $10.89: Leverage penalty (D/E 1.8): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8).
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose... Read more
Sell if holding. Multiple concerning factors at $10.89: Leverage penalty (D/E 1.8): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.0/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 15d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent Developments — MiniMed Group, Inc.
Latest news
- Number of employees of MiniMed Group, Inc. – NASDAQ:MMED - TradingView — TradingView neutral
- Is It Time To Reassess MiniMed Group (MMED) After This Year’s Sharp Share Price Fall - Yahoo Finance — Yahoo Finance negative
- B of A Securities Maintains Buy on Minimed Group, Lowers Price Target to $20 — benzinga May 18, 2026 positive
- Benchmark Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $20 — benzinga May 12, 2026 positive
- MiniMed Group Announces Health Canada License New Software For MiniMed 780G System — benzinga Apr 28, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Multiple concerning factors at $10.89: Leverage penalty (D/E 1.8): -1.0; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $10.33. Score 6.0/10, moderate confidence.
Take-profit target: $18.85 (+73.1% upside). Prior stop was $10.33. Stop-loss: $10.33.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Leverage penalty (D/E 1.8): -1.0; Elevated risk factors.
MiniMed Group, Inc. trades at a P/E of N/A (forward 16.2). TrendMatrix value score: 8.0/10. Verdict: Sell.
14 analysts cover MMED with a consensus score of 4.2/5. Average price target: $22.
What does MiniMed Group, Inc. do?MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment...
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.